S-GROUP
10.5.2023 05:01:34 CEST | Business Wire | Press release
Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. The outcome of the study will be a method freely available to all companies and organisations for the assessment of their impact on nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005817/en/
Researchers at the University of Jyväskylä have developed a method for corporations to calculate their biodiversity footprint. The pilot project focused on S Group’s biodiversity footprint. (Photo: Business Wire)
The interim report of the project published now indicates that food and fuels account for most of S Group’s biodiversity footprint, with the majority of the footprint falling on regions beyond Finland’s borders. Utility goods account for a significantly smaller portion—a few per cent—of the biodiversity footprint.
“Companies already routinely calculate their carbon footprints. This project demonstrates that they can also calculate their biodiversity footprint. A company like S Group, with operations in several different sectors, played a key role in the method’s development,” says Janne Kotiaho, Professor of Ecology at the University of Jyväskylä.
“You have to tackle climate and biodiversity challenges hand in hand. As opposed to climate efforts, biodiversity impacts are very local. The report shows that there is a need for increasingly strong cooperation between businesses and partners operating within the same geographic area. Companies must also start building new kinds of cooperation networks to reduce their negative impact on nature,” says Nina Elomaa, Senior Vice President, Sustainability, at S Group.
“You cannot manage something that you can’t measure. Stopping biodiversity loss requires a functional method for calculating biodiversity footprints. Any company that intends to make a serious effort to manage their biodiversity impact needs a method of this kind. We can take some national pride in Finland being at the forefront of this global development work,” says Lasse Miettinen, Director of Sustainability solutions at Sitra.
The theme is topical, given that nations around the world agreed on new international targets for halting biodiversity loss at the Montreal Biodiversity Conference in December. The global biodiversity framework agreed on also stated that, in the future, large and transnational companies should disclose their negative impact on biodiversity.
Biodiversity footprint maps impact on terrestrial and aquatic ecosystems
Through complex supply chains, a large part of the negative environmental impact attributable to Finnish consumption is generated across the globe, beyond Finland’s borders. According to the calculation model based on financial accounting and Finland’s international trade, more than 90 per cent of S Group’s global biodiversity footprint falls on regions outside Finland.
S Group aims to reduce its biodiversity impact through its climate work and by promoting more sustainable consumption and a planetary health diet. Concrete actions include policies related to raw materials and sourcing that aims to protect fish populations, for example, or ensure that no purchases are made from areas sensitive in terms of forest loss.
How S Group’s biodiversity footprint was assessed
The biodiversity footprint of S Group’s value chain and own operations was assessed with a method devised by the University of Jyväskylä School of Resource Wisdom – JYU.Wisdom.
The indicator of the biodiversity footprint is the share of the world’s species at risk of extinction, i.e. the Potentially Disappeared Fraction (PDF) of species. The indicator collects the PDF of various species under a single unit of measurement, similar to carbon footprint assessments, and enables the international comparison of different corporations’ biodiversity footprints.
The method’s further development continues.
For more information:
S Group - S Group (s-ryhma.fi)
JYU.Wisdom − School of Resource Wisdom — University of Jyväskylä
The Finnish Innovation Fund Sitra
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005817/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
